News
Novo Nordisk beats on Q1 earnings, cuts 2025 outlook
Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the ...
Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...
Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Novo Nordisk trades for ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
7h
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
9hon MSN
Emily Field, Barclacys head of European pharmaceuticals equity research, joins 'Squawk Box' to discuss Novo Nordisk's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback